<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224834</url>
  </required_header>
  <id_info>
    <org_study_id>VO63.08 HUN</org_study_id>
    <nct_id>NCT01224834</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Ragweed SLIT Tablets</brief_title>
  <official_title>Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets Given in Single Rising Doses and in Multi Dose Regimens to Subjects With an Allergy to Ragweed Pollen.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes Greer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stallergenes Greer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of several doses of
      ragweed pollen allergen extract administered as sublingual tablets in subjects with allergic
      rhinitis to ragweed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, tolerability as indicated by adverse events and safety laboratory evaluation assessed every day over 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological markers (IgE and IgG4)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <condition>Ragweed Pollen Allergy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual tablet of ragweed pollen allergen extract</intervention_name>
    <description>administered once a day over 10 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written consent

          -  male or female subjects from 18 yo 60 years old and in general good health

          -  for women of child bearing potential: negative urine pregnancy test and use of
             medically effective contraceptive method

          -  symptoms of ragweed pollen induced allergic rhinitis for at least the last 2 years

          -  sensitization to ragweed pollen as demonstrated with positive skin prick test to
             ragweed pollen and specific IgE level (ragweed pollen) &gt; 0.70 kU/l at screening

          -  FEV1 at least of 80% of predicted value at screening

        Exclusion Criteria:

          -  past or current disease which, as judged by the investigator, may affect the outcome
             of this study

          -  history of life-threatening asthma

          -  asthma requiring daily treatment (whatever the pharmaceutical class)

          -  pregnant or lactating women

          -  subjects who previously received desensitisation treatment to ragweed pollen and/or
             other Asteraceae or who plan to start desensitisation treatment during this study

          -  symptoms during the treatment phase due to a sensitivity to a second allergen

          -  subjects treated with ongoing immunotherapy with another allergen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Péterfai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DRC Drug Research Center, Balatonfüred - Hungary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DRC Drug Research Center</name>
      <address>
        <city>Balatonfüred</city>
        <zip>H-8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>November 5, 2010</last_update_submitted>
  <last_update_submitted_qc>November 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Olivier de Beaumont/Medical Director</name_title>
    <organization>Stallergenes SA</organization>
  </responsible_party>
  <keyword>Ragweed, allergy, sublingual immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

